<DOC>
	<DOCNO>NCT03027609</DOCNO>
	<brief_summary>Prospective , double-blind , randomized assessment efficacy , safety pharmacokinetic Aerucin® adjunct treatment ( addition standard care antibiotic ) pneumonia cause P. aeruginosa .</brief_summary>
	<brief_title>Aerucin® P. Aeruginosa Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<criteria>informed consent ≥18 year age pneumonia due P aeruginosa intubate APACHE II score 10 35 Exclusion Criteria ( main criterion ) : moribund effective antibiotic therapy ≥48 hour immunocompromised underlie pulmonary disease may preclude assessment therapeutic response</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>pneumonia</keyword>
</DOC>